Upon termination of the Transaction Agreement by the Company under specified circumstances, subject to certain exceptions, Parent will be required to pay the Company a termination fee of $225 million. Specifically, this termination fee is payable by Parent to the Company if the Transaction Agreement is terminated by the Company if Parent has (1) breached or failed to perform any of its covenants or agreements under the Transaction Agreement, resulting in the failure of a closing condition applicable to the Company that has not been cured within the specified period of time following receipt of notice from Parent of such breach, or (2) failed to consummate the Transactions, subject to a specified cure period, when all of the conditions to Parent’s obligations to consummate the closing have been satisfied or waived and the Company has notified Parent that it is ready, willing and able to consummate the Transactions at the closing. In addition, upon termination of the Transaction Agreement by the Company if Parent has breached any of its representations or warranties under the Transaction Agreement, Parent will be required to reimburse the Company’s reasonable, documented, out-of-pocket transaction expenses up to $20 million. Payment of the foregoing termination fee and expense reimbursement by Parent are the Company’s sole and exclusive monetary remedy for any breach of the Transaction Agreement by Parent or Merger Sub.
The Transaction Agreement also provides that the Company, on one hand, or Parent and Merger Sub, on the other hand, may specifically enforce the obligations under the Transaction Agreement under the terms and conditions set forth in the Transaction Agreement but in no event will the Company, on the one hand, or Parent or Merger Sub, on the other hand, be entitled to receive both their respective termination fee or expense reimbursement and a grant of specific performance
The foregoing description of the Transaction Agreement does not purport to be complete and is qualified in its entirety by the full text of the Transaction Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated by reference herein. The Transaction Agreement has been attached to provide investors with information regarding its terms. It is not intended to provide any other factual information about Vistra Corp., Parent, Merger Sub or the Company. In particular, the representations, warranties and covenants of each party set forth in the Transaction Agreement have been made only for the purposes of, and were and are solely for the benefit of the parties to, the Transaction Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosure letters made for the purposes of allocating contractual risk between the parties to the Transaction Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Accordingly, the representations and warranties may not describe the actual state of affairs at the date they were made or at any other time, and investors should not rely on them as statements of fact. These confidential disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties and certain covenants set forth in the Transaction Agreement.
Support Agreement
Concurrently with the execution of the Transaction Agreement, the Company and Parent entered into support agreements (collectively, the “Support Agreements”) with certain funds and accounts advised by Nuveen Asset Management, LLC (“Nuveen”), certain funds managed by Avenue Capital Management II, L.P. (“Avenue”) and the members of management holding the outstanding shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the “Significant Stockholders”) pursuant to which the Significant Stockholders have agreed to vote their respective shares of Company Common Stock, Series A Preferred Stock and Series B Preferred Stock (as applicable) in favor of the adoption of the Transaction Agreement, the Merger and certain other matters. Each of the Support Agreements terminates upon the first to occur of: (a) the valid termination of the Transaction Agreement in accordance with its terms; (b) the Effective Time; (c) the date of a prohibited amendment to certain terms and provisions of the Transaction Agreement; or (d) the written consent of the Significant Stockholders, Parent and the Company. The Support Agreements also contain restrictions on transfer of shares of Company Common Stock, Series A Preferred Stock and Series B Preferred Stock (as applicable) held by the Significant Stockholders, subject to certain exceptions.
The foregoing description of the Support Agreements does not purport to be complete and is qualified in its entirety by the full text of each Support Agreement, a final form of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.
Contribution and Exchange Agreements
Concurrently with the execution of the Transaction Agreement, Parent entered into contribution and exchange agreements (the “Contribution and Exchange Agreements”) with affiliates of Nuveen and Avenue (collectively, the “Rollover Holders”), pursuant to which, upon the terms and subject to the conditions thereof, the Rollover Holders will, immediately prior to the Effective Time, exchange a portion of their shares of Company Common Stock into direct or indirect equity interests of Vistra Vision (the “Rollover Shares”).
The foregoing description of the Contribution and Exchange Agreements does not purport to be complete and is qualified in its entirety by the full text of each Contribution and Exchange Agreement, a final form of which is filed as Exhibit 10.2 hereto and is incorporated by reference herein.